In early 2007 Gus and his colleagues at NYU received an investigational drug license from the FDA and the DEA as well as approval from the university to start the study.
As part of the research they administered to cancer survivors the drug psilocybin – which is the technical term for the active ingredient found in what’s commonly known as magic mushrooms.
‘When people came to our study and they took psilocybin’ said Gus ‘it was such a vastly different experience than a 22 year old who took mushrooms to go to a rave.
The sense of being assaulted by noise and loudness and people versus being quiet and the expectation of reviewing your life to find meaning.
Same medicine right?
But a very very different meaning – context and intention’.